Welcome to our dedicated page for Kiora Pharmaceuticals news (Ticker: $KPRX), a resource for investors and traders seeking the latest updates and insights on Kiora Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kiora Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kiora Pharmaceuticals's position in the market.
Rhea-AI Summary
Kiora Pharmaceuticals, Inc. has entered a strategic development and commercialization agreement with Théa Open Innovation (TOI) for the treatment of degenerative retinal diseases, excluding Asia. Kiora will receive an upfront payment of $16 million and up to $285 million upon achieving milestones, along with royalties of up to low 20% on net sales. The agreement is based on the Phase I/II data of KIO-301 in Retinitis Pigmentosa, which showed significant vision improvements in patients. KIO-301 is a small molecule designed to confer light-sensing capabilities to Retinal Ganglion Cells (RGCs) in patients with inherited retinal disease. The company will host an investor call to discuss the partnership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
53.99%
Tags
-
Rhea-AI Summary
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced its Q3 2023 financial results and plans to advance clinical development of KIO-301 for inherited retinal diseases. ABACUS-1 study showed KIO-301 is safe and tolerable, with significant improvements in visual field and brain activity. Kiora will expand clinical development of KIO-301 for multiple inherited retinal diseases, including RP, CHM, and Stargardt disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.18%
Tags
-
Rhea-AI Summary
Kiora Pharmaceuticals announces positive Phase I/II results for KIO-301, a small molecule for improving vision in patients with Retinitis Pigmentosa. The study showed significant improvement in visual field and functional vision, as well as increased brain activity in the visual cortex. The molecule is safe and well tolerated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Kiora Pharmaceuticals invites investors to view online presentation at Lytham Partners Fall 2023 Investor Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.32%
Tags
-
Rhea-AI Summary
Kiora Pharmaceuticals receives approval to enroll additional patients in ABACUS study of KIO-301 for Retinitis Pigmentosa and Choroideremia, plans to report results on November 4th. Preliminary data shows KIO-301 safe and tolerable with signs of efficacy. Kiora's 'gene mutation-agnostic approach' has potential to make an impact in both diseases. Partnership with Choroideremia Research Foundation aids in trial enrollment and future study designs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.69%
Tags
-
Rhea-AI Summary
Kiora Pharmaceuticals appoints Praveen Tyle as new Chairman, succeeding Paul Chaney. Tyle's leadership and industry experience expected to guide development of new treatments for eye disease. Tyle will continue to guide strategic direction as the Company advances development of KIO-301 for retinal diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.91%
Tags
Rhea-AI Summary
Kiora Pharmaceuticals completes patient evaluation for vision restoration drug in clinical trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
-
Rhea-AI Summary
Results from ABACUS study of KIO-301 in patients with retinitis pigmentosa to be presented at AAO 2023 conference on Nov 4, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.91%
Tags
-
Rhea-AI Summary
Kiora Pharmaceuticals adjourns Special Meeting due to lack of quorum, seeks additional votes
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
Rhea-AI Summary
Kiora Pharmaceuticals to host webinar on molecular photoswitches in retinal diseases, partnership with CRF
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
Kiora Pharmaceuticals, Inc.
Nasdaq:KPRX
KPRX Rankings
KPRX Stock Data
14.97M
19.58M
0.86%
17.61%
0.19%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
ENCINITAS
About KPRX
traded on nasdaq capital market, stock symbol eyeg, eyegate is a clinical-stage specialty pharmaceutical company that develops and commercializes products using two proprietary platform technologies for treating diseases and disorders of the eye. our most advanced platform is based on a crosslinked thiolated carboxymethyl hyaluronic acid (“cmha-s”), a modified form of the natural polymer hyaluronic acid (“ha”), which is a gel that possesses unique physical and chemical properties such as hydrating and healing when applied to the ocular surface. our first cmha-s-based product candidate, the eyegate ocular bandage gel (“obg”), is a topically applied eye drop formulation that has completed its first-in-man clinical trial for the healing and lubricating of large epithelial defects following treatment after photorefractive keratectomy (“prk”) surgery. our initial product candidate from our second platform is egp-437, incorporates a reformulated topically active corticosteroid, dexamethasone